AbbVie Inc
Performance History
| Key Stats | |
|---|---|
| Open | $138.02 |
| Prev. Close | $138.08 |
| EPS | 3.64 |
| Dividend | $5.92 |
| Next Earnings Date | Jul 27, 2023 |
| Dividend Yield % | 4.46% |
| Market Cap | $244.52B |
| PE Ratio | 38.05 |
| low | high | |
|---|---|---|
| Day Range | 137.64 | 139.09 |
| 52 Week Range | 130.96 | 168.11 |
| Ratios | |
|---|---|
| P/B Ratio | 18.23 |
| Revenue | $55.13B |
| Operating M. % | 17.76% |
| Earnings | $6.52B |
| Earnings Growth % | -55.00% |
| EBITDA Margin % | 50.77% |
| ROE % | 46.32% |
| EPS | 3.64 |
Score Breakdown
All Score (66 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| ABBV | Market | |
|---|---|---|
| Value | 40 | 42 |
| Quality | 64 | 46 |
| Ownership | 94 | 39 |
| Growth | 60 | 44 |
| Dividends | 50 | 32 |
All Score (66 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About AbbVie Inc (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- ISN
- -
- Sector
- Healthcare
- Industry
- Drug Manufacturers—General
- CEO
- Mr. Richard A. Gonzalez
- Headquarters
- North Chicago
- Employees
- 50000
Keep an eye on AbbVie Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.